Cargando…

Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer

Ovarian cancer remains the most lethal gynaecological cancer. A better understanding of the molecular pathogenesis of ovarian cancer is of critical importance to develop early detection tests and identify new therapeutic targets that would increase survival. Cancer cells depend on de novo lipid synt...

Descripción completa

Detalles Bibliográficos
Autores principales: Pyragius, Carmen E., Fuller, Maria, Ricciardelli, Carmela, Oehler, Martin K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645713/
https://www.ncbi.nlm.nih.gov/pubmed/23574936
http://dx.doi.org/10.3390/ijms14047742
_version_ 1782268529132699648
author Pyragius, Carmen E.
Fuller, Maria
Ricciardelli, Carmela
Oehler, Martin K.
author_facet Pyragius, Carmen E.
Fuller, Maria
Ricciardelli, Carmela
Oehler, Martin K.
author_sort Pyragius, Carmen E.
collection PubMed
description Ovarian cancer remains the most lethal gynaecological cancer. A better understanding of the molecular pathogenesis of ovarian cancer is of critical importance to develop early detection tests and identify new therapeutic targets that would increase survival. Cancer cells depend on de novo lipid synthesis for the generation of fatty acids to meet the energy requirements for increased tumour growth. There is increasing evidence that lipid metabolism is deregulated in cancers, including ovarian cancer. The increased expression and activity of lipogenic enzymes is largely responsible for increased lipid synthesis, which is regulated by metabolic and oncogenic signalling pathways. This article reviews the latest knowledge on lipid metabolism and the alterations in the expression of lipogenic enzymes and downstream signalling pathways in ovarian cancer. Current developments for exploiting lipids as biomarkers for the detection of early stage ovarian cancer and therapeutic targets are discussed. Current research targeting lipogenic enzymes and lipids to increase the cytotoxicity of chemotherapy drugs is also highlighted.
format Online
Article
Text
id pubmed-3645713
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-36457132013-05-13 Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer Pyragius, Carmen E. Fuller, Maria Ricciardelli, Carmela Oehler, Martin K. Int J Mol Sci Review Ovarian cancer remains the most lethal gynaecological cancer. A better understanding of the molecular pathogenesis of ovarian cancer is of critical importance to develop early detection tests and identify new therapeutic targets that would increase survival. Cancer cells depend on de novo lipid synthesis for the generation of fatty acids to meet the energy requirements for increased tumour growth. There is increasing evidence that lipid metabolism is deregulated in cancers, including ovarian cancer. The increased expression and activity of lipogenic enzymes is largely responsible for increased lipid synthesis, which is regulated by metabolic and oncogenic signalling pathways. This article reviews the latest knowledge on lipid metabolism and the alterations in the expression of lipogenic enzymes and downstream signalling pathways in ovarian cancer. Current developments for exploiting lipids as biomarkers for the detection of early stage ovarian cancer and therapeutic targets are discussed. Current research targeting lipogenic enzymes and lipids to increase the cytotoxicity of chemotherapy drugs is also highlighted. Molecular Diversity Preservation International (MDPI) 2013-04-10 /pmc/articles/PMC3645713/ /pubmed/23574936 http://dx.doi.org/10.3390/ijms14047742 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Pyragius, Carmen E.
Fuller, Maria
Ricciardelli, Carmela
Oehler, Martin K.
Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer
title Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer
title_full Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer
title_fullStr Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer
title_full_unstemmed Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer
title_short Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer
title_sort aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645713/
https://www.ncbi.nlm.nih.gov/pubmed/23574936
http://dx.doi.org/10.3390/ijms14047742
work_keys_str_mv AT pyragiuscarmene aberrantlipidmetabolismanemergingdiagnosticandtherapeutictargetinovariancancer
AT fullermaria aberrantlipidmetabolismanemergingdiagnosticandtherapeutictargetinovariancancer
AT ricciardellicarmela aberrantlipidmetabolismanemergingdiagnosticandtherapeutictargetinovariancancer
AT oehlermartink aberrantlipidmetabolismanemergingdiagnosticandtherapeutictargetinovariancancer